Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 13:14:1211506.
doi: 10.3389/fphar.2023.1211506. eCollection 2023.

Should oncologists trust cannabinoids?

Affiliations
Review

Should oncologists trust cannabinoids?

Ioana Creanga-Murariu et al. Front Pharmacol. .

Abstract

Cannabis enjoyed a "golden age" as a medicinal product in the late 19th, early 20th century, but the increased risk of overdose and abuse led to its criminalization. However, the 21st century have witnessed a resurgence of interest and a large body of literature regarding the benefits of cannabinoids have emerged. As legalization and decriminalization have spread around the world, cancer patients are increasingly interested in the potential utility of cannabinoids. Although eager to discuss cannabis use with their oncologist, patients often find them to be reluctant, mainly because clinicians are still not convinced by the existing evidence-based data to guide their treatment plans. Physicians should prescribe cannabis only if a careful explanation can be provided and follow up response evaluation ensured, making it mandatory for them to be up to date with the positive and also negative aspects of the cannabis in the case of cancer patients. Consequently, this article aims to bring some clarifications to clinicians regarding the sometimes-confusing various nomenclature under which this plant is mentioned, current legislation and the existing evidence (both preclinical and clinical) for the utility of cannabinoids in cancer patients, for either palliation of the associated symptoms or even the potential antitumor effects that cannabinoids may have.

Keywords: anorexia and cachexia; anxiety and depression; cancer; cannabinoids; cannabis; nausea and vomiting; oncology; pain.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Legal status of cannabis use. The illustration provides information on a worldwide scale, regarding the current regulations for prescribing medical cannabis, and for the recreational use (Adapted from Bio Render).

Similar articles

Cited by

References

    1. Abrams D. I. (2022). Cannabis, cannabinoids and cannabis-based medicines in cancer care. Integr. Cancer Ther. 21, 15347354221081772. 10.1177/15347354221081772 - DOI - PMC - PubMed
    1. Abuhasira R., Shbiro L., Landschaft Y. (2018). Medical use of cannabis and cannabinoids containing products - regulations in Europe and North America. Eur. J. Intern Med. 49, 2–6. 10.1016/j.ejim.2018.01.001 - DOI - PubMed
    1. Adams R., Hunt M., Clark J. H. (1940). Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. . J. Am. Chem. Soc. 62 (1), 196–200. 10.1021/ja01858a058 - DOI
    1. Adamska A., Elaskalani O., Emmanouilidi A., Kim M., Abdol Razak N. B., Metharom P., et al. (2018). Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv. Biol. Regul. 68, 77–87. 10.1016/j.jbior.2017.11.007 - DOI - PubMed
    1. Alharris E., Singh N. P., Nagarkatti P. S., Nagarkatti M. (2019). Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget 10 (1), 45–59. 10.18632/oncotarget.26534 - DOI - PMC - PubMed

Grants and funding

This work was supported by a grant of the Romanian Ministry of Education and Research, CNCS–UEFISCDI, project number PN-III-P4-ID-PCE-2020-1247, within PNCDI III.